STX.L - Shield Therapeutics plc

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
3,069
4,467
1,519
10,387
719
Cost of revenue
1,454
2,470
980
1,354
485
Gross profit
1,615
1,997
539
9,033
234
Operating expenses
Research development
7
1,072
579
2,579
2,496
Selling general and administrative
23,752
27,331
20,023
5,903
4,152
Total operating expenses
25,648
27,703
20,491
11,187
9,269
Operating income or loss
-24,033
-25,706
-19,952
-2,154
-9,035
Interest expense
-3
389
8
0
49
Income before tax
-23,410
-40,082
-19,565
-1,886
-9,066
Income tax expense
425
362
-229
744
-266
Income from continuing operations
-23,835
-40,444
-19,336
-2,630
-8,800
Net income
-23,835
-40,444
-19,336
-2,630
-8,800
Net income available to common shareholders
-23,835
-40,444
-19,336
-2,630
-8,800
Basic EPS
-
-0.17
-0.10
-0.02
-0.08
Diluted EPS
-
-0.17
-0.10
-0.02
-0.08
Basic average shares
-
237,906
204,409
120,682
120,428
Diluted average shares
-
237,906
204,409
120,682
120,428
EBITDA
-
-37,331
-17,350
819
-6,396